Loading
institutionsInstitution
HUS Comprehensive Cancer Center, Helsinki University Hospital
Finland's largest cancer centre and an OECI-accredited comprehensive cancer centre, known for hereditary cancer genetics and functional precision medicine in leukaemia.
Also called: HUS SyöpäkeskusHelsinki University Hospital Comprehensive Cancer CenterHUCH Cancer Center
Overview
The HUS Comprehensive Cancer Center is the tertiary cancer centre for the Helsinki region and a national referral centre, accredited by the OECI. University of Helsinki research includes Lauri Aaltonen's discoveries in hereditary colorectal cancer and uterine fibroid genetics, the Hematology Research Unit Helsinki (Kimmo Porkka, Satu Mustjoki) on leukaemia immunology, Sirpa Leppä's lymphoma trials for the Nordic Lymphoma Group, and the Institute for Molecular Medicine Finland, where Olli Kallioniemi's group developed drug sensitivity and resistance testing of patient leukaemia cells. The centre coordinates the national FICAN network and benefits from Finland's cancer registry and biobank infrastructure.
Location
Helsinki, FI
Type
cancer center · University of Helsinki
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#102 · 38 points (0 Newsweek + 0 NCI + 38 from 19 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Helsinki University Hospital, including child institutions. 576 works · 6,105 citations · 87% open access · 9% clinical trials · 2% reviews.
Oncology works per year
1312022
1282023
1012024
1352025
812026
Most works
- Hanna E. Seppänen36 works
- Jaana Hagström31 works
- Caj H. Haglund30 works
- Pia J. Osterlund30 works
- Paula Poikonen‐Saksela29 works
- Arto Kokkola28 works
- Sirpa Leppä27 works
- Johanna Mattson25 works
- Raija Ristamäki23 works
- Ruth Pat‐Horenczyk23 works
Most cited
- Hereditary cancer genetics
- Functional precision medicine (FIMM)
- Haematology
- Nordic lymphoma trials
- FICAN national network
Heikki Joensuu
Professor of Oncology, Helsinki University Hospital
Gastrointestinal stromal tumourAdjuvant imatinibBreast cancer trials
Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST.
Johanna Mattson
Senior Medical Director and Director of Division, HUS Comprehensive Cancer Center
OncologyCancer centre managementRadiotherapy and chemotherapy services
Oncologist who directs the HUS Comprehensive Cancer Center in Helsinki, Finland's largest cancer treatment centre.
Similar pages
- InstitutionOulu University Hospital
Shares Tays Cancer Centre, Tampere University Hospital, Finnish Cancer Center (FICAN), Organisation of European Cancer Institutes.
- PersonSatu Tiainen
Shares Kuopio University Hospital Cancer Center, Finnish Cancer Center (FICAN).
- PersonAnnika Auranen
Shares Tays Cancer Centre, Tampere University Hospital, Finnish Cancer Center (FICAN).
- PersonPia Vihinen
Shares Turku University Hospital Cancer Centre, Finnish Cancer Center (FICAN).
- InstitutionInstituto Português de Oncologia do Porto Francisco Gentil
Shares Inherited risk is mostly unidentified, Germline (hereditary) testing, Organisation of European Cancer Institutes, CAR-T cell therapy.
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares Germline vs somatic mutations, Inherited risk is mostly unidentified, Germline (hereditary) testing, HR-positive / HER2-negative breast cancer.
- PersonArto Mannermaa
Shares Kuopio University Hospital Cancer Center, Organisation of European Cancer Institutes.
- PersonSirkku Jyrkkiö
Shares Turku University Hospital Cancer Centre, Organisation of European Cancer Institutes.